IP Library Patent Application 17074200
Patent Application
App. No. 17/074,200

USE OF PDL1 EXPRESSING CELLS TO CONVERT T CELLS INTO REGULATORY T CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/074,200
Abstract

The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.

Claims (6)

1 - 6 . (canceled)

7 . A converted T cell produced by a method comprising contacting a T cell with a K562 cell modified to comprise an agent capable of activating PD1 signaling in said T cell thereby converting said T cell into a cell that exhibits a regulatory T cell phenotype.

8 . The method of claim 7 , wherein said agent is selected from the group consisting of PDL1, PDL2, PD1 ligand, and an anti-PD1 antibody.

9 . A method for inhibiting alloreactive T cells, the method comprising contacting said alloreactive T cells with an effective amount of converted Tregs.

10 . A method for inhibiting cytotoxic T-lymphocyte (CTL) activity, the method comprising contacting a cytotoxic T-lymphocyte with an effective amount of converted Tregs.

11 - 16 . (canceled)